Scienture Holdings Announces FDA Approval for ArbliTM

The latest update is out from Scienture Holdings ( (SCNX) ).

On March 17, 2025, Scienture Holdings, Inc. entered into a consulting agreement with Draper, Inc. to enhance its investor relations and business development, agreeing to pay Draper in restricted shares. The agreement aims to support Scienture’s financial strategies and market positioning. Additionally, on March 18, 2025, Scienture announced FDA approval for ArbliTM, a novel oral liquid formulation of losartan potassium, marking a significant milestone as it is the first FDA-approved liquid losartan in the U.S. This product targets hypertension and related conditions, offering a convenient alternative to existing solid formulations, and is expected to launch commercially in Q3 2025.

More about Scienture Holdings

SCIENTURE HOLDINGS, INC. (NASDAQ: SCNX) is a pharmaceutical company that, through its subsidiaries Scienture, LLC and Integra Pharma Solutions, LLC, focuses on developing and distributing novel specialty products to address unmet market needs. The company provides value to patients, physicians, and caregivers by offering branded and generic pharmaceutical products across various therapeutic areas.

YTD Price Performance: -68.33%

Average Trading Volume: 2,868,395

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: $14.3M

For detailed information about SCNX stock, go to TipRanks’ Stock Analysis page.